President Trump Orders Cannabis Reclassified to Schedule III

In a significant move for the cannabis industry, President Donald Trump has signed an executive order directing federal agencies to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This decision marks a pivotal shift in federal drug policy, potentially easing restrictions on cannabis research and opening doors for medical advancements. The order reflects a growing recognition of the therapeutic potential of cannabis, aligning federal regulations more closely with the existing state-level legal frameworks

The executive order, announced during a press briefing, aims to facilitate enhanced research into the medical benefits and risks of cannabis. President Trump emphasized the importance of this reclassification, stating that it will enable more comprehensive studies into marijuana's health impacts. This move is expected to significantly impact the medical community by providing a clearer path for research into cannabis as a treatment for various health conditions, including those treated with hemp-derived cannabinoid products

The reclassification of cannabis to Schedule III is expected to bridge the gap between current medical usage and scientific understanding. President Trump highlighted the need for real-world evidence and affordable access to medical cannabis and CBD products, particularly for vulnerable populations such as adolescents and young adults. The executive order outlines the administration's commitment to advancing medical marijuana research and ensuring that patients and doctors are better informed about the potential benefits and risks associated with cannabis use

The decision to reclassify cannabis follows recommendations from the U.S. Department of Health and Human Services (HHS), which had conducted a scientific evaluation at the direction of President Joe Biden. The Drug Enforcement Administration (DEA) will now review these recommendations, as it holds the final authority to reschedule drugs under the Controlled Substances Act. This move could take effect within 30 days, provided there are no legal challenges, setting a new precedent for federal cannabis regulation

The cannabis industry has welcomed this development as a long-awaited acknowledgment of the plant's medicinal value. Organizations like the National Cannabis Industry Association (NCIA) and Realm of Caring have praised the decision, noting its potential to enhance research opportunities and provide regulatory clarity. They stress the importance of establishing federal standards for manufacturing, testing, and consumer safety, which could lead to a more robust and reliable cannabis market. However, industry leaders continue to urge further legislative action to support state rights and responsible cannabis operators